Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
TECX Quote, Financials, Valuation and Earnings
Last price:
$34.07
Seasonality move
:
-9.09%
Day range:
$31.91 - $35.80
52-week range:
$13.70 - $36.03
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.68x
Volume:
1.1M
Avg. volume:
528.8K
1-year change:
46.68%
Market cap:
$673.5M
Revenue:
--
EPS (TTM):
-$4.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TECX
Tectonic Therapeutic, Inc.
|
-- | -- | -- | -50.01% | $78.25 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 16.03% | -30.17% | $31.85 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
MRNA
Moderna, Inc.
|
$623.9M | -$2.64 | 121.94% | -16.92% | $42.90 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TECX
Tectonic Therapeutic, Inc.
|
$35.87 | $78.25 | $673.5M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.58 | $31.85 | $3.8B | 9.87x | $0.00 | 0% | 3.57x |
|
AGEN
Agenus, Inc.
|
$3.15 | $12.33 | $113.8M | -- | $0.00 | 0% | 0.80x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$323.59 | $457.00 | $42.9B | 143.37x | $0.00 | 0% | 11.63x |
|
MRNA
Moderna, Inc.
|
$55.74 | $42.90 | $22B | -- | $0.00 | 0% | 11.15x |
|
SVRA
Savara, Inc.
|
$5.27 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TECX
Tectonic Therapeutic, Inc.
|
0.51% | 0.520 | 0.33% | 26.32x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
510.35% | 3.128 | 285.06% | 0.03x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
MRNA
Moderna, Inc.
|
13.11% | -0.006 | 11.23% | 3.01x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TECX
Tectonic Therapeutic, Inc.
|
-$333K | -$21.5M | -29.55% | -29.79% | -- | -$14.5M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
MRNA
Moderna, Inc.
|
$159M | -$857M | -26.82% | -29.19% | -126.4% | $891M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Tectonic Therapeutic, Inc. vs. Competitors
-
Which has Higher Returns TECX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of 96.33%. Tectonic Therapeutic, Inc.'s return on equity of -29.79% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.03 $252.6M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About TECX or ACAD?
Tectonic Therapeutic, Inc. has a consensus price target of $78.25, signalling upside risk potential of 118.15%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 41.05%. Given that Tectonic Therapeutic, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Tectonic Therapeutic, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is TECX or ACAD More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.582, which suggesting that the stock is 58.185% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock TECX or ACAD?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or ACAD?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Tectonic Therapeutic, Inc.'s net income of -$19.2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus 3.57x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19.2M ACADACADIA Pharmaceuticals, Inc.3.57x 9.87x $284M $273.6M
-
Which has Higher Returns TECX or AGEN?
Agenus, Inc. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of -116.82%. Tectonic Therapeutic, Inc.'s return on equity of -29.79% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.03 $252.6M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About TECX or AGEN?
Tectonic Therapeutic, Inc. has a consensus price target of $78.25, signalling upside risk potential of 118.15%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 291.53%. Given that Agenus, Inc. has higher upside potential than Tectonic Therapeutic, Inc., analysts believe Agenus, Inc. is more attractive than Tectonic Therapeutic, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 AGENAgenus, Inc.2 1 0 -
Is TECX or AGEN More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.582, which suggesting that the stock is 58.185% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.
-
Which is a Better Dividend Stock TECX or AGEN?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or AGEN?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Tectonic Therapeutic, Inc.'s net income of -$19.2M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus 0.80x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19.2M AGENAgenus, Inc.0.80x -- $30.2M $63.9M
-
Which has Higher Returns TECX or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of 16.99%. Tectonic Therapeutic, Inc.'s return on equity of -29.79% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.03 $252.6M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About TECX or ALNY?
Tectonic Therapeutic, Inc. has a consensus price target of $78.25, signalling upside risk potential of 118.15%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 41.23%. Given that Tectonic Therapeutic, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Tectonic Therapeutic, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is TECX or ALNY More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.582, which suggesting that the stock is 58.185% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock TECX or ALNY?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or ALNY?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Tectonic Therapeutic, Inc.'s net income of -$19.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 143.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus 11.63x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19.2M ALNYAlnylam Pharmaceuticals, Inc.11.63x 143.37x $1.1B $186.4M
-
Which has Higher Returns TECX or MRNA?
Moderna, Inc. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of -121.83%. Tectonic Therapeutic, Inc.'s return on equity of -29.79% beat Moderna, Inc.'s return on equity of -29.19%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.03 $252.6M MRNAModerna, Inc.23.45% -$2.11 $10B -
What do Analysts Say About TECX or MRNA?
Tectonic Therapeutic, Inc. has a consensus price target of $78.25, signalling upside risk potential of 118.15%. On the other hand Moderna, Inc. has an analysts' consensus of $42.90 which suggests that it could fall by -23.04%. Given that Tectonic Therapeutic, Inc. has higher upside potential than Moderna, Inc., analysts believe Tectonic Therapeutic, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 MRNAModerna, Inc.2 18 1 -
Is TECX or MRNA More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.582, which suggesting that the stock is 58.185% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.087%.
-
Which is a Better Dividend Stock TECX or MRNA?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or MRNA?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than Moderna, Inc. quarterly revenues of $678M. Tectonic Therapeutic, Inc.'s net income of -$19.2M is higher than Moderna, Inc.'s net income of -$826M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus 11.15x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19.2M MRNAModerna, Inc.11.15x -- $678M -$826M
-
Which has Higher Returns TECX or SVRA?
Savara, Inc. has a net margin of -- compared to Tectonic Therapeutic, Inc.'s net margin of --. Tectonic Therapeutic, Inc.'s return on equity of -29.79% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital TECXTectonic Therapeutic, Inc.-- -$1.03 $252.6M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About TECX or SVRA?
Tectonic Therapeutic, Inc. has a consensus price target of $78.25, signalling upside risk potential of 118.15%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 105.17%. Given that Tectonic Therapeutic, Inc. has higher upside potential than Savara, Inc., analysts believe Tectonic Therapeutic, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TECXTectonic Therapeutic, Inc.6 0 0 SVRASavara, Inc.6 0 0 -
Is TECX or SVRA More Risky?
Tectonic Therapeutic, Inc. has a beta of 1.582, which suggesting that the stock is 58.185% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock TECX or SVRA?
Tectonic Therapeutic, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tectonic Therapeutic, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TECX or SVRA?
Tectonic Therapeutic, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Tectonic Therapeutic, Inc.'s net income of -$19.2M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Tectonic Therapeutic, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tectonic Therapeutic, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TECXTectonic Therapeutic, Inc.-- -- -- -$19.2M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
47
GSIW alert for Mar 10
Garden Stage Ltd. [GSIW] is up 278.41% over the past day.
Sell
44
TECX alert for Mar 10
Tectonic Therapeutic, Inc. [TECX] is down 5.02% over the past day.
Buy
67
BNAI alert for Mar 10
Brand Engagement Network, Inc. [BNAI] is down 25.47% over the past day.
